Drreddys Laboratories | RDY - Operating Profit


Drreddys Laboratories reported INR14.33B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
Bayer EUR -543M 556M Sep/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
GlaxoSmithKline GBP 2.79B 764M Sep/2025
Hikma Pharmaceutical USD 187M 95M Jun/2025
Lonza CHF 430M 104M Dec/2024
Novartis USD 4.5B 363M Sep/2025
Pacira USD 13.15M 2.92M Sep/2025
Prestige Brands USD 79.67M 7.91M Sep/2025
Richter Gedeon HUF 63.58B 132M Sep/2025
Sun Pharmaceuticals INR 33.67B 49.9M Sep/2025
Supernus Pharmaceuticals USD -60.18M 72.32M Sep/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025